Engimmune Therapeutics appoints Annalisa D’Andrea to board of directors
Swiss biotech Engimmune Therapeutics has announced that it has appointed Dr Annalisa D’Andrea to its board of directors as a non-executive director, effective from 1 June 2023.
D’Andreabringswithherover25yearsofexperience inthelifesciencesindustryfromimmunologyresearch and drug discovery and development to strategic leadership in biotechnology and pharmaceutical companies. She is also a venture partner at Longwood Fund and was previously president and chief scientific officer of ImmuneID. Before this she worked as chief scientific officer at Kiniksa Pharmaceuticals and vice presidentandglobalheadofdiscoveryforimmunology and inflammation at Roche. She has also previously held various executive roles at SRI International, as well as working at Chiron Vaccines early in her career. Bent Jakobsen PhD, chairman of Engimmune’s board of directors, commented: "We are delighted to welcome Dr Annalisa D’Andrea to the board with her extensive proven experience of managing and growing novel healthcare start-up companies, developing important treatments to help patients. Her expertise and significant drug discovery experience will be invaluable as we continue to further develop our novel pipeline of soluble, multi-specific T-cell receptor therapies.”
D’Andrea, added: "I am delighted to be joining Engimmune Therapeutics at an exciting and important phase of development as the Company strives to develop new multi-specific TCR therapies for the treatment and benefit of patients with cancer and autoimmune diseases. I look forward to working with the team and using my vast experience to assist with advancing its proprietary platform technologies through discovery and development of highly potent and specific TCR-based therapeutic products.”